Neoadjuvant Therapies for Patients with Locally Advanced Gastric Cancer: A Retrospective Cohort Study

Background: Gastric cancer is the second main cause of cancer-related deaths, Since the disease does not produce typical symptoms in the early periods, diagnosis is usually made in locally advanced stages, Although surgery is the most curative treatment, neoadjuvant chemotherapy (NACT) occupies a hi...

Full description

Saved in:
Bibliographic Details
Published in:The Eurasian journal of medicine 2024-06, Vol.56 (2), p.121-126
Main Authors: Agirman, Enes, Albayrak, Yavuz, Peksoz, Rifat, Fakirullahoglu, Mesud, Uygur, Furkan Ali, Disci, Esra, Yildirgan, Mehmet Ilhan, Atamanalp, Sabri Selcuk
Format: Article
Language:English
Subjects:
Care and treatment
Clinical Study
Development and progression
Diagnosis
Dosage and administration
Neoadjuvant therapy
Original
Patient outcomes
Stomach cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Gastric cancer is the second main cause of cancer-related deaths, Since the disease does not produce typical symptoms in the early periods, diagnosis is usually made in locally advanced stages, Although surgery is the most curative treatment, neoadjuvant chemotherapy (NACT) occupies a highly important place in prognosis, Methods: Patients operated due to locally advanced gastric cancer (LAGC) in 2015-2022 were investigated retrospectively. These were divided into 2 groups, NACT + surgery + adjuvant chemotherapy (AC) (group I) and surgery-ACT (group 2), The patients' clinicopathological characteristics and postoperative outcomes were compared, Overall survival (OS) and disease-free survival (DFS) analyses were also performed, Results: Eighty-four patients who underwent surgery following NACT and 60 resectable patients who underwent surgery and then received ACT were evaluated, The patients' mean age was 62,96 years, and 61,8% were men, Perineural and lymphovascular invasion, total lymph nodes removed, and numbers of metastatic lymph nodes were significantly higher in group 2 (P
ISSN:1308-8734
1308-8742
DOI:10.5152/eurasianjmed.2024.24468